A groundbreaking development in the treatment of pancreatic cancer has emerged with the analysis of clinical trials conducted by Dr. Monique Yohanan on the drug Rasonque from Revolution Medicines. The trial revealed that patients with stage 4 pancreatic cancer experienced a median survival of 13.2 months, a significant improvement from the 6.7 months survival with conventional chemotherapy. This advancement provides renewed hope in combating a disease traditionally marked by a three percent survival rate for stage 4 cases.
At a major international cancer conference, early results from the trial were presented, which indicated that an experimental pill, when paired with standard chemotherapy, effectively reduced or halted tumor growth in the majority of patients with advanced pancreatic cancer. The trial results were shared at the EORTC-NCI-AACR Symposium in Barcelona, stemming from a phase 1/2 trial that tested an oral medication called daraxonrasib alongside two standard intravenous chemotherapy drugs, gemcitabine and nab-paclitaxel. This trial focused on 61 patients whose pancreatic cancer had metastasized and who had not yet received treatment for their advanced condition.
Pancreatic cancer is notably hard to treat, as over half of the diagnoses occur after the disease has spread. Standard chemotherapy treatments typically shrink tumors in 23% to 42% of cases, yet the cancer often recurs within five to six months, leading to survival rates between eight and eleven months. The combination of daraxonrasib and standard chemotherapy reduced tumors or stopped cancer growth in 90.2% of patients who had not received prior treatment for advanced pancreatic cancer.
According to the National Cancer Institute, only around 3% of patients with pancreatic cancer in distant-stage live five years post-diagnosis. The study, which monitored participants for an average of 18 months, found a reduction in tumor size in 60.7% of cases, with complete disappearance on scans in 8.2%. Overall, the treatment halted tumor growth in 90.2% of participants. Patients experienced a median duration of 12.8 months before the cancer worsened, nearly double the average timeline with chemotherapy alone, with 76.6% of patients alive at the one-year point.
“We are now seeing not only substantial tumor shrinkages, including complete responses, but also durable disease control, with median progression-free survival exceeding one year,” expressed Dr. Wungki Park, study lead and a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center.
The trial indicated that most side effects, such as rash, diarrhea, fatigue, and low blood cell counts, were manageable through standard care. Only 5% of patients discontinued treatment due to side effects associated with daraxonrasib. Approximately 90% of pancreatic cancers are driven by mutations in a gene termed RAS, which facilitates tumor growth. Daraxonrasib is tailored to inhibit this growth signal effectively.
Dr. Elena Garralda, symposium chair and co-director of the clinical research program at the Vall d’Hebron Institute of Oncology, affirmed that these findings demonstrate the potential of RAS-targeted drugs when combined with existing therapies to yield longer-lasting benefits.
Despite these promising results, researchers noted limitations within the findings. As an early-phase study involving 61 individuals, all participants received the experimental drug combination, lacking a control group for direct comparison with standard chemotherapy. This limitation means the superiority of the new regimen and its extension of overall survival cannot yet be confirmed. A larger, randomized phase 3 trial, RASolute-303, is underway to compare the effects of daraxonrasib, alone and in combination, against standard chemotherapy.
The trial, conducted under the funding of Revolution Medicines, is expected to clarify these early results and establish whether the benefits provide extended survival. Researchers are considering applying findings to other RAS mutation-driven cancers, such as lung, colorectal, and gynecological cancers, though separate studies would be necessary for confirmation.
